跳至主要内容
临床试验/NCT02782819
NCT02782819Unknown不适用

A Randomized Controlled Trial of Crystalloid Alone Versus Crystalloid Plus Colloid in Shock Resuscitation

Mahidol University1 个研究点 分布在 1 个国家目标入组 320 人开始时间: 2014年9月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
320
试验地点
1
主要终点
Proportion of patients who had shock reversal

研究概览

简要总结

Fluid resuscitation is the most effective treatment of shock. Isotonic crystalloid solution is the current recommended initial fluid resuscitation. However, this kind of fluid has high volume of distribution and may require large volume administration before achieve therapeutic goal of shock reversal. There are rising concern about the delay in shock reversal and adverse consequences of large amount volume of fluid therapy. Colloid fluid have been used as the alternate fluid resuscitation, aiming to limit the volume of fluid resuscitation and promote shock reversal. Whether colloid infusion can improve shock reversal rate and decrease complication associated with fluid resuscitation, had inconclusive information.

详细描述

Fluid resuscitation is the most effective treatment of shock. Isotonic crystalloid solution is the current recommended initial fluid resuscitation. However, this kind of fluid has high volume of distribution and may require large volume administration before achieve therapeutic goal of shock reversal. There are rising concern about the delay in shock reversal and adverse consequences of large amount volume of fluid therapy. Colloid fluid have been used as the alternate fluid resuscitation, aiming to limit the volume of fluid resuscitation and promote shock reversal. Data from a recent randomized controlled study showed the improve long term survival among shock patients whose resuscitated with colloid solution. There were evidence about the increase incidence of acute kidney injury among critically ill patients who received hydroxyethyl starch, a previously worldwide used colloid solution. For septic shock, the leading cause of shock in current situation, resuscitation with albumin may associated with better outcome, while increasing mortality had been reported among the patient who received hydroxyethyl starch. Whether colloid infusion can improve shock reversal rate and decrease complication associated with fluid resuscitation, had inconclusive information.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age at least 18 years old
  • New onset of shock within 24 hours
  • Mean arterial blood pressure less than 65 mmHg or systolic blood pressure less than 60% of patient's baseline blood pressure
  • Evidence of poor tissue perfusion including: urine output less than 0.5 mL/kg/hr, lactate more than 2 mmol/L, alteration of consciousness without other explanation
  • Evidence of fluid inadequacy (CVP < 12 mmHg, Pulmonary capillary wedge pressure < 18 mmHg) or evidence of fluid responsive (IVC diameter variation > 15%, pulse pressure variation > 15%, positive fluid challenge test)

排除标准

  • Prolong shock more than 24 hours
  • Received colloid solution more than 1,000 mL in previous 72 hours
  • Do not resuscitation documented patient
  • Contraindication for fluid therapy including: suspected cardiogenic shock, evidence of pulmonary edema, history of anaphylaxis after fluid therapy

研究组 & 干预措施

Crystalloid

Placebo Comparator

Isotonic crystalloid solution resuscitation

干预措施: Isotonic crystalloid solution resuscitation (Drug)

Crystalloid plus Colloid

Active Comparator

Colloid solution resuscitation

干预措施: Isotonic crystalloid solution resuscitation (Drug)

Crystalloid plus Colloid

Active Comparator

Colloid solution resuscitation

干预措施: Colloid solution resuscitation (Drug)

结局指标

主要结局

Proportion of patients who had shock reversal

时间窗: 6 hours after initial resuscitation

Shock reversal was defined by mean arterial blood pressure \> 65 mmHg plus lactate clearance more than 10%

次要结局

  • Hospital mortality(90 days)
  • Total fluid resuscitation within 24 hours(24 hours)
  • Mortality rate(28 days)
  • Renal replacement therapy(28 days)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Surat Tongyoo

Assistant Professor

Mahidol University

研究点 (1)

Loading locations...

相似试验